Symposium: microtracer AMS for next-gen drug development
Pioneering progress: early human ADME data for accelerated drug development
Save the date: March 26, 2026
Peregrion organizes its 2nd AMS symposium.
For our program we have the privilege to showcase an impressive lineup of international speakers who will share how they leveraged the microtracer AMS approach to tackle diverse ADME challenges and how the microtracer approach helped to accelerate drug development.
Location: Fletcher Wellness-Hotel Leiden
Address: Bargelaan 180, 2333 CW Leiden
If your mandate is to develop life‑changing therapies faster while de‑risking development, this year ’s Peregrion symposium is one you can’ t afford to miss.
Meet our speakers
Holger Scheible
PhD, Scientific Director – Head of Biotransformation, Merck KGaA
Dr Holger Scheible obtained his PhD in Medicinal Chemistry in 2007 from the University of Tübingen, where he worked on the pharmacokinetics and metabolism of novel p38 MAP kinase inhibitors.
He is currently Head of Biotransformation within NCE DMPK at Merck Healthcare KGaA.
Stefan Blech
PhD, Director Bioanalysis, DMPK, Boehringer Ingelheim
Dr Stefan Blech is Director of the Bioanalysis Group within the global DMPK department at Boehringer Ingelheim in Biberach, Germany.
He holds a PhD in Chemistry from the University of Cologne and specializes in bioanalysis, drug metabolism, pharmacokinetics, and mass spectrometry.
Ronald Kong
PhD, Vice President Clinical Pharmacology & DMPK at PTC Therapeutics
Dr Ronald Kong joined PTC Therapeutics in 2007 and currently serves as Vice President of Clinical Pharmacology & DMPK.
Previously, he held leadership roles in Drug Metabolism and Pharmacokinetics at Lundbeck Research USA and Purdue Pharma.
Aram Oganesian
PhD, Vice President Clinical Pharmacology at Taiho Oncology
Dr Aram Oganesian received his PhD in Toxicology from Oregon State University and is a Diplomate of the American Board of Toxicology. He works at Taiho Oncology Inc.
With over 25 years of experience in early discovery, nonclinical development, and clinical pharmacology, he previously spent 12 years at Wyeth Research (Pfizer).
Xiaomin Wang
PhD, Scientific Director at Bristol Myers Squibb
Dr Xiaomin Wang received his PhD in Physical Chemistry from York University in Toronto, Canada.
He is Scientific Director of Bioanalysis and Precision Medicine at Bristol Myers Squibb, specializing in oncology and immunology, and has contributed to six FDA-approved New Drug Applications since joining Celgene/BMS in 2007.
Kees Groen
PhD, CEO & Co-founder, DGr Pharma
Dr Kees Groen holds a PhD in Pharmaceutical Sciences and has extensive experience in ADME, mathematical modelling, and drug development consultancy for small molecules and biologics.
He previously founded Kinesis Pharma BV and co-founded LAP&P Consultants, a modelling and simulation company.
Discover how microtracer AMS unlocks early human ADME insight to cut uncertainty and shape clinical development programs
Sign Up Now
I attended the Human Microtracer Studies Symposium in Leiden (April 21st, 2022) and found it exceptionally valuable.
The symposium featured high-quality presentations and brought together leading experts in the field. The networking opportunities were outstanding – connecting with fellow specialists provided insights that extended well beyond the formal sessions.
Holger Scheible
PhD, Head of Biotransformation within NCE DMPK at Merck Healthcare KGaA
Scientific Poster Presentations
Celerion
Aernout Van Haarst
Predictive Value of Nonclinical ADME Findings for Clinical Excretion Routes
Sanofi
Zied Kaabia
14C-Oditrasertib – Impact of radiolabel positioning optimization from preclinical to clinical phases
Peregrion
Jelle Reinen
Integration of automated sample processing with Accelerator Mass Spectrometry
Debiopharm
Dany Spaggiari
Mass Balance, Pharmacokinetics and Metabolism of the Antimicrobial Afabicin following Intravenous and Oral Administration in Humans
Quotient & Peregrion
Lotte van Andel
Investigation of the Metabolite Profile of Acoziborole in Plasma, Urine and Fecal Homogenate Samples Using UPLC-MS Fractionation Followed by AMS Analysis
Merck
Holger Scheible
Microtracer-based assessment of the mass balance, pharmacokinetics, and excretion of [14C]-berzosertib, an intravenous ATR inhibitor, in patients with advanced solid tumors
Quotient
Iain Shaw
A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]-Acoziborole in Healthy Male Subjects After Oral Dosing
Pfizer
Chris Healy
Examination of Human Absorption, Distribution, Metabolism and Excretion of Ritlecitinib by Accelerator Mass Spectrometry
TNO
Canxia Shi
Obicetrapib alone and in combination with ezetimibe increases reverse cholesterol transport and does not affect VLDL production
Following the success of its first edition, Peregrion now organizes the second international symposium on AMS.
Peregrion’s 2nd AMS symposium 2026 is limited to a maximum of 150 participants, ensuring an exclusive and high-impact experience for every guest.